
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1018780/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. European Journal of Cancer, 2015, 51, 2777-2784.	2.8	282
2	A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus. Clinical Cancer Research, 2006, 12, 6064-6072.	7.0	260
3	Screening for Distant Metastases in Patients With Head and Neck Cancer. Laryngoscope, 2000, 110, 397-401.	2.0	247
4	Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial. Journal of Clinical Oncology, 2012, 30, 1777-1783.	1.6	222
5	Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discovery, 2019, 9, 852-871.	9.4	222
6	<scp>COVID</scp> â€19 pandemic: Effects and evidenceâ€based recommendations for otolaryngology and head and neck surgery practice. Head and Neck, 2020, 42, 1259-1267.	2.0	218
7	Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients. Clinical Cancer Research, 2006, 12, 2133-2140.	7.0	207
8	Feasibility of using head and neck CT imaging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncology, 2016, 62, 28-33.	1.5	189
9	Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncology, 2017, 71, 26-33.	1.5	172
10	Staging and grading of oral squamous cell carcinoma: An update. Oral Oncology, 2020, 107, 104799.	1.5	172
11	Radiation Dosimetry of ⁸⁹ Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2009, 50, 1828-1836.	5.0	154
12	Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head and Neck, 2013, 35, 123-132.	2.0	146
13	Update on primary head and neck mucosal melanoma. Head and Neck, 2016, 38, 147-155.	2.0	143
14	Distress in Spouses and Patients After Treatment for Head and Neck Cancer. Laryngoscope, 2007, 117, 238-241.	2.0	140
15	Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1024-1030.	6.4	139
16	Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncology, 2012, 48, 775-779.	1.5	139
17	European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results of the treatment of skin cancer. European Journal of Cancer, 2016, 63, 41-52.	2.8	137
18	Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting. Frontiers in Oncology, 2019, 9, 827.	2.8	126

#	Article	IF	CITATIONS
19	Role of eHealth application Oncokompas in supporting self-management of symptoms and health-related quality of life in cancer survivors: a randomised, controlled trial. Lancet Oncology, The, 2020, 21, 80-94.	10.7	121
20	Employment and return to work in head and neck cancer survivors. Oral Oncology, 2010, 46, 56-60.	1.5	114
21	Vascularized tissue to reduce fistula following salvage total laryngectomy: A systematic review. Laryngoscope, 2014, 124, 1848-1853.	2.0	114
22	Joint Practice Guidelines for Radionuclide Lymphoscintigraphy for Sentinel Node Localization in Oral/Oropharyngeal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2009, 16, 3190-3210.	1.5	108
23	Novel insights into pathological changes in muscular arteries of radiotherapy patients. Radiotherapy and Oncology, 2009, 92, 477-483.	0.6	106
24	Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to reirradiate. Head and Neck, 2015, 37, 134-150.	2.0	106
25	Percutaneous Dilatational Tracheostomy in the ICU. Chest, 2003, 123, 1595-1602.	0.8	105
26	Management of frey syndrome. Head and Neck, 2007, 29, 773-778.	2.0	100
27	Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients. BMC Cancer, 2017, 17, 428.	2.6	99
28	Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer. European Archives of Oto-Rhino-Laryngology, 2019, 276, 1475-1486.	1.6	99
29	Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. Radiotherapy and Oncology, 2008, 87, 221-229.	0.6	97
30	Comorbid condition as a prognostic factor for complications in major surgery of the oral cavity and oropharynx with microvascular soft tissue reconstruction. Head and Neck, 2003, 25, 808-815.	2.0	93
31	Swallowing after major surgery of the oral cavity or oropharynx: A prospective and longitudinal assessment of patients treated by microvascular soft tissue reconstruction. Head and Neck, 2007, 29, 638-647.	2.0	93
32	Management of adult soft tissue sarcomas of the head and neck. Oral Oncology, 2010, 46, 786-790.	1.5	92
33	Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. Oral Oncology, 2009, 45, 386-393.	1.5	83
34	Quality of life after surgical treatment for oral and oropharyngeal cancer: A prospective longitudinal assessment of patients reconstructed by a microvascular flap. Oral Oncology, 2007, 43, 1034-1042.	1.5	80
35	Salvage laryngectomy: Oncological and functional outcome. Oral Oncology, 2011, 47, 296-301.	1.5	80
36	Prospective evaluation of health-related quality of life in long-term oral and oropharyngeal cancer survivors and the perceived need for supportive care. Oral Oncology, 2013, 49, 443-448.	1.5	80

#	Article	IF	CITATIONS
37	Computerized prospective screening for high levels of emotional distress in head and neck cancer patients and referral rate to psychosocial care. Oral Oncology, 2009, 45, e129-e133.	1.5	77
38	Intraoral ultrasonography to measure tumor thickness of oral cancer: A systematic review and meta-analysis. Oral Oncology, 2018, 77, 29-36.	1.5	77
39	Surgical consensus guidelines on sentinel node biopsy (SNB) in patients with oral cancer. Head and Neck, 2019, 41, 2655-2664.	2.0	77
40	Modern reconstruction techniques for oral and pharyngeal defects after tumor resection. European Archives of Oto-Rhino-Laryngology, 2008, 265, 1-9.	1.6	76
41	Proposal for a rational classification of neck dissections. Head and Neck, 2011, 33, 445-450.	2.0	76
42	Sentinel lymph node biopsy in clinically N0 T1–T2 staged oral cancer: The Dutch multicenter trial. Oral Oncology, 2014, 50, 1020-1024.	1.5	75
43	The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: A prospective cohort study. Radiotherapy and Oncology, 2014, 110, 422-428.	0.6	73
44	FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 3884-3893.	7.0	73
45	European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: Results from the treatment of mucosal cancers. European Journal of Cancer, 2017, 87, 172-181.	2.8	72
46	Preoperative low skeletal muscle mass as a risk factor for pharyngocutaneous fistula and decreased overall survival in patients undergoing total laryngectomy. Head and Neck, 2019, 41, 1745-1755.	2.0	72
47	Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer, 2006, 106, 1536-1547.	4.1	70
48	Sentinel node biopsy for earlyâ€stage oral cavity cancer: the VU University Medical Center experience. Head and Neck, 2015, 37, 573-578.	2.0	70
49	Prevalence of swallowing and speech problems in daily life after chemoradiation for head and neck cancer based on cut-off scores of the patient-reported outcome measures SWAL-QOL and SHI. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1849-1855.	1.6	69
50	Screening for distant metastases in patients with head and neck cancer: Is there a role for 18FDG-PET?. Oral Oncology, 2006, 42, 275-280.	1.5	68
51	Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. European Archives of Oto-Rhino-Laryngology, 2007, 264, 651-657.	1.6	68
52	Evaluation of Donor Site Function and Morbidity of the Fasciocutaneous Radial Forearm Flap. Laryngoscope, 2004, 114, 1973-1976.	2.0	67
53	Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 1829-1839.	2.0	67
54	Screening for Distant Metastases in Patients With Head and Neck Cancer: Is Chest Computed Tomography Sufficient?. Laryngoscope, 2005, 115, 1813-1817.	2.0	66

#	Article	IF	CITATIONS
55	Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1915-1936.	6.4	66
56	Outcome of patients with early stage oral cancer managed by an observation strategy towards the NO neck using ultrasound guided fine needle aspiration cytology: No survival difference as compared to elective neck dissection. Oral Oncology, 2013, 49, 157-164.	1.5	66
57	Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation. Head and Neck, 2009, 31, 593-603.	2.0	65
58	Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunology, Immunotherapy, 2003, 52, 576-582.	4.2	64
59	Patient-Derived Head and Neck Cancer Organoids Recapitulate EGFR Expression Levels of Respective Tissues and Are Responsive to EGFR-Targeted Photodynamic Therapy. Journal of Clinical Medicine, 2019, 8, 1880.	2.4	64
60	Elective neck dissection in oral squamous cell carcinoma: Past, present and future. Oral Oncology, 2019, 90, 87-93.	1.5	62
61	Surgical options in benign parotid tumors: a proposal for classification. European Archives of Oto-Rhino-Laryngology, 2017, 274, 3825-3836.	1.6	62
62	Diffusion-Weighted Imaging of the Head and Neck in Healthy Subjects: Reproducibility of ADC Values in Different MRI Systems and Repeat Sessions. American Journal of Neuroradiology, 2015, 36, 384-390.	2.4	61
63	Cervical Lymph Node Metastasis in High-Grade Transformation of Head and Neck Adenoid Cystic Carcinoma: A Collective International Review. Advances in Therapy, 2016, 33, 357-368.	2.9	61
64	Contemporary management of primary parapharyngeal space tumors. Head and Neck, 2019, 41, 522-535.	2.0	61
65	Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 915-926.	2.0	60
66	Speech outcome after surgical treatment for oral and oropharyngeal cancer: A longitudinal assessment of patients reconstructed by a microvascular flap. Head and Neck, 2005, 27, 785-793.	2.0	58
67	Donor site morbidity of the fasciocutaneous radial forearm flap: what does the patient really bother?. European Archives of Oto-Rhino-Laryngology, 2007, 264, 929-934.	1.6	58
68	Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 125, 478-486.	0.4	58
69	Positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET) in the clinically negative neck: is it likely to be superior?. European Archives of Oto-Rhino-Laryngology, 2004, 261, 479-483.	1.6	57
70	Management of the facial nerve in parotid cancer: preservation or resection and reconstruction. European Archives of Oto-Rhino-Laryngology, 2018, 275, 2615-2626.	1.6	57
71	Intravoxel incoherent motion magnetic resonance imaging in head and neck cancer: A systematic review of the diagnostic and prognostic value. Oral Oncology, 2017, 68, 81-91.	1.5	55
72	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. Critical Reviews in Oncology/Hematology, 2019, 137, 84-91.	4.4	55

#	Article	IF	CITATIONS
73	Novel diagnostic modalities for assessment of the clinically node-negative neck in oral squamous-cell carcinoma. Lancet Oncology, The, 2012, 13, e554-e561.	10.7	53
74	Quality of life as predictor of survival: A prospective study on patients treated with combined surgery and radiotherapy for advanced oral and oropharyngeal cancer. Radiotherapy and Oncology, 2010, 97, 258-262.	0.6	52
75	Prophylactic exercises among head and neck cancer patients during and after swallowing sparing intensity modulated radiation: adherence and exercise performance levels of a 12-week guided home-based program. European Archives of Oto-Rhino-Laryngology, 2017, 274, 1129-1138.	1.6	52
76	Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome. Advances in Therapy, 2018, 35, 153-160.	2.9	52
77	What is the role of sentinel lymph node biopsy in the management of oral cancer in 2010?. European Archives of Oto-Rhino-Laryngology, 2010, 267, 839-844.	1.6	51
78	Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2013, 270, 1569-1580.	1.6	51
79	Prognostic value of lymph node ratio in head and neck squamous cell carcinoma. Head and Neck, 2018, 40, 1082-1090.	2.0	51
80	Chest CT and Whole-Body 18F-FDG PET Are Cost-Effective in Screening for Distant Metastases in Head and Neck Cancer Patients. Journal of Nuclear Medicine, 2010, 51, 176-182.	5.0	50
81	Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trial. Annals of Oncology, 2016, 27, 1754-1760.	1.2	50
82	Surgical margins in head and neck cancer: Intra- and postoperative considerations. Auris Nasus Larynx, 2019, 46, 10-17.	1.2	50
83	Elective Neck Dissection or Sentinel Lymph Node Biopsy in Early Stage Oral Cavity Cancer Patients: The Dutch Experience. Cancers, 2020, 12, 1783.	3.7	50
84	Outcome prediction of head and neck squamous cell carcinoma by MRI radiomic signatures. European Radiology, 2020, 30, 6311-6321.	4.5	49
85	Repeated Botulinum Toxin Type A Injections to Treat Patients With Frey Syndrome. JAMA Otolaryngology, 2009, 135, 287.	1.2	48
86	Paratracheal lymph node dissection in cancer of the larynx, hypopharynx, and cervical esophagus: The need for guidelines. Head and Neck, 2011, 33, 912-916.	2.0	48
87	Pilot Study on the Feasibility of PET/CT Lymphoscintigraphy with ⁸⁹ Zr-Nanocolloidal Albumin for Sentinel Node Identification in Oral Cancer Patients. Journal of Nuclear Medicine, 2013, 54, 585-589.	5.0	48
88	Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults. Head and Neck, 2017, 39, 140-146.	2.0	48
89	Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. Oral Oncology, 2020, 101, 104530.	1.5	48
90	The risk of second primary tumors in head and neck cancer: A systematic review. Head and Neck, 2020, 42, 456-466.	2.0	47

#	Article	IF	CITATIONS
91	Interobserver agreement of skeletal muscle mass measurement on head and neck CT imaging at the level of the third cervical vertebra. European Archives of Oto-Rhino-Laryngology, 2019, 276, 1175-1182.	1.6	46
92	Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy in Locally Advanced Head-and-Neck Squamous Cell Cancer: The ECLYPS Study. Journal of Clinical Oncology, 2017, 35, 3458-3464.	1.6	45
93	Selective neck dissection in surgically treated head and neck squamous cell carcinoma patients with a clinically positive neck: Systematic review. European Journal of Surgical Oncology, 2018, 44, 395-403.	1.0	45
94	Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1161-1168.	6.4	44
95	Evaluation of the use of freehand SPECT for sentinel node biopsy in early stage oral carcinoma. Oral Oncology, 2015, 51, 287-290.	1.5	44
96	Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement. European Archives of Oto-Rhino-Laryngology, 2004, 261, 417-22.	1.6	43
97	The prevalence of hypothyroidism after treatment for laryngeal and hypopharyngeal carcinomas: are autoantibodies of influence?. Acta Oto-Laryngologica, 2007, 127, 312-317.	0.9	43
98	Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial. BMC Cancer, 2012, 12, 173.	2.6	43
99	Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer. Clinical Cancer Research, 2014, 20, 1345-1354.	7.0	43
100	Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review. Oral Oncology, 2019, 88, 75-83.	1.5	43
101	Submandibular approach for excision of a large schwannoma in the base of the tongue. European Archives of Oto-Rhino-Laryngology, 2000, 257, 283-286.	1.6	42
102	Advances in imaging in the work-up of head and neck cancer patients. Oral Oncology, 2009, 45, 930-935.	1.5	42
103	Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiotherapy and Oncology, 2013, 108, 517-522.	0.6	42
104	Polymorphous adenocarcinoma of the salivary glands: reappraisal and update. European Archives of Oto-Rhino-Laryngology, 2018, 275, 1681-1695.	1.6	42
105	Systematic review: Accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head and Neck, 2008, 30, 889-897.	2.0	41
106	⁸⁹ Zr-Nanocolloidal Albumin–Based PET/CT Lymphoscintigraphy for Sentinel Node Detection in Head and Neck Cancer: Preclinical Results. Journal of Nuclear Medicine, 2011, 52, 1580-1584.	5.0	41
107	The history of sentinel node biopsy in head and neck cancer: From visualization of lymphatic vessels to sentinel nodes. Oral Oncology, 2015, 51, 819-823.	1.5	41
108	Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1614-1621.	6.4	41

#	Article	IF	CITATIONS
109	Distant metastases from head and neck squamous cell carcinoma. Part III. Treatment. Oral Oncology, 2012, 48, 787-793.	1.5	40
110	Patient-reported symptom questionnaires in laryngeal cancer: Voice, speech and swallowing. Oral Oncology, 2014, 50, 759-764.	1.5	40
111	Predictive value of diffusion-weighted imaging without and with including contrast-enhanced magnetic resonance imaging in image analysis of head and neck squamous cell carcinoma. European Journal of Radiology, 2015, 84, 108-116.	2.6	40
112	The potential use of big data in oncology. Oral Oncology, 2019, 98, 8-12.	1.5	40
113	Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma. Journal of Clinical Pathology, 2018, 71, 267-274.	2.0	39
114	Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy. European Journal of Radiology, 2019, 113, 39-50.	2.6	38
115	Sentinel node biopsy for oral and oropharyngeal squamous cell carcinoma in the previously treated neck. Oral Oncology, 2012, 48, 85-89.	1.5	37
116	Contrast-enhanced perfusion magnetic resonance imaging for head and neck squamous cell carcinoma: A systematic review. Oral Oncology, 2015, 51, 124-138.	1.5	37
117	An online self-care education program to support patients after total laryngectomy: feasibility and satisfaction. Supportive Care in Cancer, 2016, 24, 1261-1268.	2.2	37
118	Durable usage of patient-reported outcome measures in clinical practice to monitor health-related quality of life in head and neck cancer patients. Supportive Care in Cancer, 2017, 25, 3775-3783.	2.2	37
119	Influence of tumor and microenvironment characteristics on diffusion-weighted imaging in oropharyngeal carcinoma: A pilot study. Oral Oncology, 2018, 77, 9-15.	1.5	37
120	Assessment of tumour depth in early tongue cancer: Accuracy of MRI and intraoral ultrasound. Oral Oncology, 2020, 110, 104895.	1.5	37
121	Shoulder morbidity after non-surgical treatment of the neck. Radiotherapy and Oncology, 2009, 90, 196-201.	0.6	36
122	Sentinel node biopsy using 3D lymphatic mapping by freehand SPECT in early stage oral cancer: a new technique. Clinical Otolaryngology, 2012, 37, 89-90.	1.2	36
123	Malignant lymphoma of mucosa-associated lymphoid tissue in the larynx. European Archives of Oto-Rhino-Laryngology, 1998, 255, 368-370.	1.6	34
124	Screening for distant metastases in patients with head and neck cancer: what is the current clinical practice?. Clinical Otolaryngology, 2005, 30, 438-443.	1.2	34
125	Indicators for Enteral Nutrition Use and Prophylactic Percutaneous Endoscopic Gastrostomy Placement in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy. Nutrition in Clinical Practice, 2017, 32, 225-232.	2.4	34
126	Management of extracranial arteriovenous malformations of the head and neck. Auris Nasus Larynx, 2020, 47, 181-190.	1.2	34

#	Article	IF	CITATIONS
127	Perioperative Antibiotics in Clean-Contaminated Head and Neck Surgery: A Systematic Review and Meta-Analysis. Advances in Therapy, 2020, 37, 1360-1380.	2.9	34
128	The eHealth self-management application â€~Oncokompas' that supports cancer survivors to improve health-related quality of life and reduce symptoms: which groups benefit most?. Acta Oncológica, 2021, 60, 403-411.	1.8	34
129	Computerized monitoring of patient-reported speech and swallowing problems in head and neck cancer patients in clinical practice. Supportive Care in Cancer, 2012, 20, 2925-2931.	2.2	33
130	Multiparametric functional MRI and 18F-FDG-PET for survival prediction in patients with head and neck squamous cell carcinoma treated with (chemo)radiation. European Radiology, 2021, 31, 616-628.	4.5	33
131	Second primary tumours in oral cancer. Oral Oncology, 2010, 46, 426-428.	1.5	32
132	Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review. Auris Nasus Larynx, 2016, 43, 477-484.	1.2	32
133	Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. Auris Nasus Larynx, 2017, 44, 18-25.	1.2	32
134	Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma. Oral Oncology, 2020, 101, 104519.	1.5	32
135	Distant metastases from head and neck squamous cell carcinoma. Part II. Diagnosis. Oral Oncology, 2012, 48, 780-786.	1.5	31
136	Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and 18F-FDG-PET–CT. Oral Oncology, 2015, 51, 541-547.	1.5	31
137	Targeted sequencing reveals <i>TP53</i> as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. Oncotarget, 2016, 7, 61575-61586.	1.8	31
138	Deep lobe parotidectomy—why, when, and how?. European Archives of Oto-Rhino-Laryngology, 2017, 274, 4073-4078.	1.6	31
139	Diagnostic value of diffusion-weighted imaging and 18F-FDG-PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis. European Journal of Radiology, 2018, 107, 20-25.	2.6	31
140	Prognostic role of intraparotid lymph node metastasis in primary parotid cancer: Systematic review. Head and Neck, 2021, 43, 997-1008.	2.0	31
141	Sentinel Node in Oral Cancer. Clinical Nuclear Medicine, 2016, 41, 534-542.	1.3	30
142	Cost–utility of sentinel lymph node biopsy in cT1–T2N0 oral cancer. Oral Oncology, 2016, 53, 20-26.	1.5	30
143	Depth of invasion in patients with early stage oral cancer staged by sentinel node biopsy. Head and Neck, 2019, 41, 2100-2106.	2.0	30
144	The added value of SPECT-CT for the identification of sentinel lymph nodes in early stage oral cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 998-1004.	6.4	29

#	Article	IF	CITATIONS
145	Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe. EJNMMI Research, 2018, 8, 15.	2.5	29
146	Predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with head and neck squamous cell carcinoma. EJNMMI Research, 2020, 10, 102.	2.5	29
147	Implications of a positive sentinel node in oral squamous cell carcinoma. Head and Neck, 2012, 34, 1580-1585.	2.0	28
148	A prospective longitudinal study on endocrine dysfunction following treatment of laryngeal or hypopharyngeal carcinoma. Oral Oncology, 2013, 49, 950-955.	1.5	28
149	Fusion of Freehand SPECT and Ultrasound to Perform Ultrasound-Guided Fine-Needle Aspiration Cytology of Sentinel Nodes in Head and Neck Cancer. American Journal of Neuroradiology, 2015, 36, 2153-2158.	2.4	28
150	A Participatory Design Approach to Develop a Web-Based Self-Care Program Supporting Early Rehabilitation among Patients after Total Laryngectomy. Folia Phoniatrica Et Logopaedica, 2015, 67, 193-201.	1.1	28
151	Cost-Utility of Stepped Care Targeting Psychological Distress in Patients With Head and Neck or Lung Cancer. Journal of Clinical Oncology, 2017, 35, 314-324.	1.6	28
152	Predictive factors for pharyngocutaneous fistulization after total laryngectomy: a Dutch Head and Neck Society audit. European Archives of Oto-Rhino-Laryngology, 2018, 275, 783-794.	1.6	28
153	Sentinel lymph node detection in oral cancer: a within-patient comparison between [99mTc]Tc-tilmanocept and [99mTc]Tc-nanocolloid. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 851-858.	6.4	28
154	Severe comorbidity negatively influences prognosis in patients with oral and oropharyngeal cancer after surgical treatment with microvascular reconstruction. Oral Oncology, 2005, 41, 358-364.	1.5	27
155	Recent advances in surgery for head and neck cancer. Current Opinion in Oncology, 2010, 22, 186-193.	2.4	27
156	What is the role of sentinel lymph node biopsy in the management of oral cancer in 2020?. European Archives of Oto-Rhino-Laryngology, 2021, 278, 3181-3191.	1.6	27
157	De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed?. Oral Oncology, 2021, 123, 105620.	1.5	27
158	Visualization of the sentinel node in early-stage oral cancer. Nuclear Medicine Communications, 2012, 33, 1065-1069.	1.1	26
159	Pretreatment screening on distant metastases and head and neck cancer patients: Validation of risk factors and influence on survival. Oral Oncology, 2015, 51, 267-271.	1.5	26
160	Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature. Oral Oncology, 2017, 75, 8-15.	1.5	26
161	Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond. Head and Neck, 2017, 39, 2329-2349.	2.0	26
162	Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients. Oral Oncology, 2019, 99, 104341.	1.5	26

#	Article	IF	CITATIONS
163	New Developments in Imaging for Sentinel Lymph Node Biopsy in Early-Stage Oral Cavity Squamous Cell Carcinoma. Cancers, 2020, 12, 3055.	3.7	26
164	The efficacy of Life Review Therapy combined with Memory Specificity Training (LRT-MST) targeting cancer patients in palliative care: A randomized controlled trial. PLoS ONE, 2018, 13, e0197277.	2.5	25
165	Overcoming wound complications in head and neck salvage surgery. Auris Nasus Larynx, 2018, 45, 1135-1142.	1.2	25
166	Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer, 2020, 20, 519.	2.6	25
167	Incidence of Occult Lymph Node Metastasis in Primary Larynx Squamous Cell Carcinoma, by Subsite, T Classification and Neck Level: A Systematic Review. Cancers, 2020, 12, 1059.	3.7	25
168	Parameters Associated With Mandibular Osteoradionecrosis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1276-1280.	1.3	24
169	The role of age in treatmentâ€related adverse events in patients with head and neck cancer: A systematic review. Head and Neck, 2019, 41, 2410-2429.	2.0	24
170	Validation of the G8 screening tool in older patients with cancer considered for surgical treatment. Journal of Geriatric Oncology, 2021, 12, 793-798.	1.0	24
171	Feasibility study of ultrasound-guided resection of tongue cancer with immediate specimen examination to improve margin control – Comparison with conventional treatment. Oral Oncology, 2021, 116, 105249.	1.5	24
172	Diffusion-weighted EPI- and HASTE-MRI and 18F-FDG-PET-CT early during chemoradiotherapy in advanced head and neck cancer. Quantitative Imaging in Medicine and Surgery, 2014, 4, 239-50.	2.0	24
173	How we do it: Chemo-electroporation in the head and neck for otherwise untreatable patients. Clinical Otolaryngology, 2006, 31, 447-451.	0.0	23
174	Second primary lung cancers following a diagnosis of primary head and neck cancer. Lung Cancer, 2015, 88, 94-99.	2.0	23
175	Interaction of quantitative ¹⁸ Fâ€FDGâ€PETâ€CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. Head and Neck, 2016, 38, 529-535.	2.0	23
176	High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment. Oral Oncology, 2019, 94, 68-72.	1.5	23
177	Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. Frontiers in Oncology, 2020, 10, 593164.	2.8	23
178	Fewer head and neck cancer diagnoses and faster treatment initiation during COVID-19 in 2020: A nationwide population-based analysis. Radiotherapy and Oncology, 2022, 167, 42-48.	0.6	23
179	Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. Clinical Cancer Research, 2002, 8, 3401-6.	7.0	23
180	Radioimmunodetection and radioimmunotherapy of head and neck cancer. Oral Oncology, 2004, 40, 761-772.	1.5	22

#	Article	IF	CITATIONS
181	Shoulder morbidity after pectoralis major flap reconstruction. Head and Neck, 2016, 38, 1221-1228.	2.0	22
182	The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 3780.	2.4	22
183	Improved detection of recurrent laryngeal tumor after radiotherapy using 18FDG-PET as initial method. Radiotherapy and Oncology, 2008, 87, 217-220.	0.6	21
184	Sentinel lymph node biopsy in oral and oropharyngeal squamous cell carcinoma: current status and unresolved challenges. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1469-1480.	6.4	21
185	Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors. Cancer Immunology, Immunotherapy, 2020, 69, 581-591.	4.2	21
186	Severe atherosclerosis of the radial artery in a free radial forearm flap precluding its use. Oral Oncology, 2004, 40, 99-102.	1.5	20
187	A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. Contemporary Clinical Trials, 2007, 28, 705-712.	1.8	20
188	Effectiveness of an 18F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. Radiotherapy and Oncology, 2016, 118, 251-256.	0.6	20
189	The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1562-1565.	6.4	19
190	Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2013, 270, 1981-1989.	1.6	19
191	The real additional value of FDG-PET in detecting the occult primary tumour in patients with cervical lymph node metastases of unknown primary tumour. European Archives of Oto-Rhino-Laryngology, 2010, 267, 1653-1655.	1.6	18
192	Electrochemotherapy in Mucosal Cancer of the Head and Neck: A Systematic Review. Cancers, 2021, 13, 1254.	3.7	18
193	The association between skeletal muscle measures and chemotherapyâ€induced toxicity in nonâ€small cell lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1554-1564.	7.3	18
194	Elective neck dissection versus observation in the clinically node negative neck in early oral cancer: Do we have the answer yet?. Oral Oncology, 2015, 51, 963-965.	1.5	17
195	Cervical Lymph Node Metastasis in Adenoid Cystic Carcinoma of the Larynx: A Collective International Review. Advances in Therapy, 2016, 33, 553-579.	2.9	17
196	Management of the clinically node negative neck in squamous cell carcinoma of the maxilla. Oral Oncology, 2017, 66, 87-92.	1.5	17
197	68Ca-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma. Nuclear Medicine and Molecular Imaging, 2017, 51, 360-361.	1.0	17
198	Detection of Distant Metastases in Head and Neck Cancer: Changing Landscape. Advances in Therapy, 2018, 35, 161-172.	2.9	17

#	Article	IF	CITATIONS
199	Effectiveness of a guided self-help exercise program tailored to patients treated with total laryngectomy: Results of a multi-center randomized controlled trial. Oral Oncology, 2020, 103, 104586.	1.5	17
200	Sarcopenia measured with handgrip strength and skeletal muscle mass to assess frailty in older patients with head and neck cancer. Journal of Geriatric Oncology, 2021, 12, 434-440.	1.0	17
201	Current Trends and Controversies in the Management of Warthin Tumor of the Parotid Gland. Diagnostics, 2021, 11, 1467.	2.6	17
202	Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: Is there a role for autofluorescence bronchoscopy?. Lung Cancer, 2008, 62, 309-315.	2.0	16
203	Paratracheal lymph node dissection does not negatively affect thyroid dysfunction in patients undergoing laryngectomy. European Archives of Oto-Rhino-Laryngology, 2010, 267, 807-810.	1.6	16
204	Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: A feasibility study. European Journal of Radiology, 2014, 83, 1144-1151.	2.6	16
205	Radiologic extranodal spread and matted nodes: Important predictive factors for development of distant metastases in patients with highâ€risk head and neck cancer. Head and Neck, 2016, 38, E1452-8.	2.0	16
206	Screening for distant metastases in head and neck cancer patients using FDG-PET and chest CT: validation of an algorithm. European Archives of Oto-Rhino-Laryngology, 2016, 273, 2643-2650.	1.6	16
207	Prediction model for tube feeding dependency during chemoradiotherapy for at least four weeks in head and neck cancer patients: A tool for prophylactic gastrostomy decision making. Clinical Nutrition, 2020, 39, 2600-2608.	5.0	16
208	Low skeletal muscle mass predicts frailty in elderly head and neck cancer patients. European Archives of Oto-Rhino-Laryngology, 2022, 279, 967-977.	1.6	16
209	Percutaneous Tracheostomy in the Intensive Care Unit: Which Safety Precautions?. Critical Care Medicine, 2001, 29, 221-222.	0.9	16
210	Effectiveness and cost-utility of a guided self-help exercise program for patients treated with total laryngectomy: protocol of a multi-center randomized controlled trial. BMC Cancer, 2016, 16, 580.	2.6	15
211	Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group. European Archives of Oto-Rhino-Laryngology, 2016, 273, 1557-1567.	1.6	15
212	The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy. European Archives of Oto-Rhino-Laryngology, 2020, 277, 2847-2858.	1.6	15
213	[68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy: a novel technique for sentinel lymph node imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 963-965.	6.4	15
214	First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer. EJNMMI Research, 2021, 11, 126.	2.5	15
215	Sentinel node identification in laryngeal cancer: Feasible in primary cancer with previously untreated neck. Oral Oncology, 2013, 49, 165-168.	1.5	14
216	Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes. European Archives of Oto-Rhino-Laryngology, 2017, 274, 961-968.	1.6	14

#	Article	IF	CITATIONS
217	Humour and laughing in patients with prolonged incurable cancer: an ethnographic study in a comprehensive cancer centre. Quality of Life Research, 2020, 29, 2425-2434.	3.1	14
218	Early Response Prediction of Multiparametric Functional MRI and 18F-FDG-PET in Patients with Head and Neck Squamous Cell Carcinoma Treated with (Chemo)Radiation. Cancers, 2022, 14, 216.	3.7	14
219	Accurate detection of circulating tumor DNA using nanopore consensus sequencing. Npj Genomic Medicine, 2021, 6, 106.	3.8	14
220	Interobserver Variability in Chest CT and Whole Body FDG-PET Screening for Distant Metastases in Head and Neck Cancer Patients. Molecular Imaging and Biology, 2011, 13, 385-390.	2.6	13
221	A comprehensive assessment protocol including patient reported outcomes, physical tests, and biological sampling in newly diagnosed patients with head and neck cancer: is it feasible?. Supportive Care in Cancer, 2014, 22, 3321-3330.	2.2	13
222	Sacrifice and extracranial reconstruction of the common or internal carotid artery in advanced head and neck carcinoma: Review and metaâ€analysis. Head and Neck, 2018, 40, 1305-1320.	2.0	13
223	An evidence-based analysis of the management of N0 neck in patients with cancer of the parotid gland. Expert Review of Anticancer Therapy, 2019, 19, 899-908.	2.4	13
224	Feasibility of assessment of skeletal muscle mass on a single cross-sectional image at the level of the fourth thoracic vertebra. European Journal of Radiology, 2021, 142, 109879.	2.6	13
225	Radioimmunotherapy in patients with head and neck squamous cell carcinoma: Initial experience. Head and Neck, 2001, 23, 559-565.	2.0	12
226	The potential role of non-FDG-PET in the management of head and neck cancer. Oral Oncology, 2011, 47, 2-7.	1.5	12
227	Postoperative elective nodal irradiation for squamous cell carcinoma of the head and neck: outcome and prognostic factors for regional recurrence. Annals of Oncology, 2011, 22, 2489-2494.	1.2	12
228	Which is the most reliable diagnostic modality for detecting locally residual or recurrent laryngeal squamous cell carcinoma after (chemo)radiotherapy?. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2787-2791.	1.6	12
229	Dilation after laryngectomy: Incidence, risk factors and complications. Oral Oncology, 2019, 91, 107-112.	1.5	12
230	Contralateral Regional Recurrence in Lateralized or Paramedian Early-Stage Oral Cancer Undergoing Sentinel Lymph Node Biopsy—Comparison to a Historic Elective Neck Dissection Cohort. Frontiers in Oncology, 2021, 11, 644306.	2.8	12
231	The association of pretreatment low skeletal muscle mass with chemotherapy doseâ€limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with highâ€dose cisplatin. Head and Neck, 2022, 44, 189-200.	2.0	12
232	Patient reported voice outcome in recurrent respiratory papillomatosis. Laryngoscope, 2010, 120, 188-192.	2.0	11
233	Detecting hypothyroidism after treatment for laryngeal or hypopharyngeal carcinomas: a nationwide survey in The Netherlands. European Archives of Oto-Rhino-Laryngology, 2009, 266, 713-718.	1.6	11
234	Practice variation in defining sentinel lymph nodes on lymphoscintigrams in oral cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 2249-2256.	6.4	11

#	Article	IF	CITATIONS
235	Removing the Taboo on the Surgical Violation (Cut-Through) of Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 1010.	2.2	11
236	Cytokeratin 19 expression in early oral squamous cell carcinoma and their metastasis: Inadequate biomarker for one-step nucleic acid amplification implementation in sentinel lymph node biopsy procedure. Head and Neck, 2017, 39, 1864-1868.	2.0	11
237	Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients. Acta Oncológica, 2018, 57, 1687-1692.	1.8	11
238	Validation of skeletal muscle mass assessment at the level of the third cervical vertebra in patients with head and neck cancer. Oral Oncology, 2021, 123, 105617.	1.5	11
239	The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study. European Journal of Cancer, 2021, , .	2.8	11
240	Sarcopenia and its impact in head and neck cancer treatment. Current Opinion in Otolaryngology and Head and Neck Surgery, 2022, 30, 87-93.	1.8	11
241	Indications and extent of elective neck dissection in patients with early stage oral and oropharyngeal carcinoma: nationwide survey in The Netherlands. Journal of Laryngology and Otology, 2009, 123, 889-898.	0.8	10
242	Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known. European Radiology, 2020, 30, 1228-1231.	4.5	10
243	The Additional Value of Ultrafast DCE-MRI to DWI-MRI and 18F-FDG-PET to Detect Occult Primary Head and Neck Squamous Cell Carcinoma. Cancers, 2020, 12, 2826.	3.7	10
244	Locoregional recurrence rate and diseaseâ€specific survival following marginal vs segmental resection for oral squamous cell carcinoma with mandibular bone invasion. Journal of Surgical Oncology, 2020, 122, 646-652.	1.7	10
245	Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1075-1082.	6.4	10
246	Adherence to pretreatment and intratreatment imaging of head and neck squamous cell carcinoma patients undergoing (chemo) radiotherapy in a research setting. Clinical Imaging, 2021, 69, 82-90.	1.5	10
247	The need for patients' endocrine function vigilance following treatment of head and neck cancer. Current Opinion in Otolaryngology and Head and Neck Surgery, 2008, 16, 154-157.	1.8	9
248	Response evaluation after chemoradiotherapy for advanced staged oropharyngeal squamous cell carcinoma: a nationwide survey in the Netherlands. European Archives of Oto-Rhino-Laryngology, 2015, 272, 3507-3513.	1.6	9
249	When is reoperative surgery not indicated for recurrent head and neck squamous cell carcinoma?. European Archives of Oto-Rhino-Laryngology, 2015, 272, 259-262.	1.6	9
250	Patients' perspective on the impact of sentinel node biopsy in oral cancer treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 122, 279-286.	0.4	9
251	Demographic, clinical, lifestyle-related, and social-cognitive correlates of physical activity in head and neck cancer survivors. Supportive Care in Cancer, 2018, 26, 1447-1456.	2.2	9
252	Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F–FDG-PET-CT and/or diffusion-weighted MRI. BMC Cancer, 2017, 17, 256.	2.6	9

#	Article	IF	CITATIONS
253	Use of Diffusion-Weighted Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Combined With Computed Tomography in the Response Assessment for (Chemo)radiotherapy in Head and Neck Squamous Cell Carcinoma. Clinical Oncology, 2018, 30, 780-792.	1.4	9
254	Optimizing Survival Predictions of Hypopharynx Cancer: Development of a Clinical Prediction Model. Laryngoscope, 2020, 130, 2166-2172.	2.0	9
255	Electrochemotherapy in the head and neck area: an addition to the treatment armamentarium. Current Opinion in Otolaryngology and Head and Neck Surgery, 2020, 28, 112-117.	1.8	9
256	HIFâ€l a expression and differential effects on survival in patients with oral cavity, larynx, and oropharynx squamous cell carcinomas. Head and Neck, 2021, 43, 745-756.	2.0	9
257	Cost-utility and cost-effectiveness of a guided self-help head and neck exercise program for patients treated with total laryngectomy: Results of a multi-center randomized controlled trial. Oral Oncology, 2021, 117, 105306.	1.5	9
258	A complete magnetic sentinel lymph node biopsy procedure in oral cancer patients: A pilot study. Oral Oncology, 2021, 121, 105464.	1.5	9
259	Presence of Human Papillomavirus and Epstein–Barr Virus, but Absence of Merkel Cell Polyomavirus, in Head and Neck Cancer of Non-Smokers and Non-Drinkers. Frontiers in Oncology, 2020, 10, 560434.	2.8	9
260	Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review. Cancer Management and Research, 2022, Volume 14, 339-366.	1.9	9
261	Efficacy of the eHealth application Oncokompas, facilitating incurably ill cancer patients to self-manage their palliative care needs: A randomized controlled trial. Lancet Regional Health - Europe, The, 2022, 18, 100390.	5.6	9
262	How to analyze the diagnostic value of sentinel node biopsy in head and neck cancer. European Archives of Oto-Rhino-Laryngology, 2013, 270, 789-791.	1.6	8
263	Molecular profile of nasopharyngeal carcinoma: analysing tumour suppressor gene promoter hypermethylation by multiplex ligation-dependent probe amplification. Journal of Clinical Pathology, 2018, 71, 351-359.	2.0	8
264	Prospective comparative study of MRI including diffusion-weighted images versus FDG PET-CT for the detection of recurrent head and neck squamous cell carcinomas after (chemo)radiotherapy. European Journal of Radiology, 2019, 111, 62-67.	2.6	8
265	Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy. Journal of Clinical Medicine, 2021, 10, 1762.	2.4	8
266	Qualitative and Quantitative Diagnosis in Head and Neck Cancer. Diagnostics, 2021, 11, 1526.	2.6	8
267	Masseter muscle parameters can function as an alternative for skeletal muscle mass assessments on cross-sectional imaging at lumbar or cervical vertebral levels. Quantitative Imaging in Medicine and Surgery, 2022, 12, 15-27.	2.0	8
268	Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer. European Archives of Oto-Rhino-Laryngology, 2022, 279, 3685-3694.	1.6	8
269	Clinical value of ¹⁸ <scp>FDG PET</scp> / <scp>CT</scp> in screening for distant metastases in head and neck squamous cell carcinoma. Clinical Otolaryngology, 2018, 43, 875-881.	1.2	7
270	Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: which groups specifically benefit? Secondary analyses of a randomized controlled trial. Supportive Care in Cancer, 2019, 27, 4543-4553.	2.2	7

#	Article	IF	CITATIONS
271	The Current Indications for Non-Surgical Treatment of Hypopharyngeal Cancer. Advances in Oto-Rhino-Laryngology, 2019, 83, 76-89.	1.6	7
272	Considerations for environmentally sustainable head and neck surgical oncology practice. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2020, 41, 102719.	1.3	7
273	Dysphagia, trismus and speech impairment following radiation-based treatment for advanced stage oropharyngeal carcinoma: a one-year prospective evaluation. European Archives of Oto-Rhino-Laryngology, 2022, 279, 1003-1027.	1.6	7
274	Managing Cachexia in Head and Neck Cancer: a Systematic Scoping Review. Advances in Therapy, 2022, 39, 1502-1523.	2.9	7
275	Measurement of Sarcopenia in Head and Neck Cancer Patients and Its Association With Frailty. Frontiers in Oncology, 2022, 12, .	2.8	7
276	Implications of the MSLT-1 for sentinel lymph node biopsy in cutaneous head and neck melanoma. Oral Oncology, 2015, 51, 629-633.	1.5	6
277	A nation-wide epidemiological study on the risk of developing second malignancies in patients with different histological subtypes of nasopharyngeal carcinoma. Oral Oncology, 2016, 56, 40-46.	1.5	6
278	An international comparison of the management of the neck in early oral squamous cell carcinoma in the Netherlands, UK, and USA. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 62-69.	1.7	6
279	The adverse impact of surveillance intervals on the sensitivity of FDC-PET/CT for the detection of distant metastases in head and neck cancer patients. European Archives of Oto-Rhino-Laryngology, 2017, 274, 1113-1120.	1.6	6
280	ls Câ€11 Methionine PET an alternative to 18â€F FDGâ€PET for identifying recurrent laryngeal cancer after radiotherapy?. Clinical Otolaryngology, 2019, 44, 124-130.	1.2	6
281	Oral squamous cell carcinoma involving the maxillae: Factors affecting local recurrence and the value of salvage treatment for overall survival. Head and Neck, 2020, 42, 1821-1828.	2.0	6
282	High CXCR4 expression in adenoid cystic carcinoma of the head and neck is associated with increased risk of locoregional recurrence. Journal of Clinical Pathology, 2020, 73, 476-482.	2.0	6
283	Diagnostic accuracy of [^{99m} Tc]Tcâ€tilmanocept compared to [^{99m} Tc]Tcâ€nanocolloid for sentinel lymph node identification in earlyâ€stage oral cancer. Clinical Otolaryngology, 2021, 46, 1383-1388.	1.2	6
284	Target Definition in MR-Guided Adaptive Radiotherapy for Head and Neck Cancer. Cancers, 2022, 14, 3027.	3.7	6
285	The potential of FDG-PET in the detection of occult lymph node metastasis: importance of patient selection and reference standard. European Archives of Oto-Rhino-Laryngology, 2013, 270, 2173-2174.	1.6	5
286	Percutaneous Irreversible Electroporation for Recurrent Thyroid Cancer—A Case Report. Journal of Vascular and Interventional Radiology, 2015, 26, 1180-1182.	0.5	5
287	Pretreatment screening for distant metastases in the Dutch head and neck centers: 10Âyears later. European Archives of Oto-Rhino-Laryngology, 2016, 273, 3287-3291.	1.6	5
288	Depression and related factors after oral oncological treatment: a 5-year prospective cohort study. Supportive Care in Cancer, 2021, 29, 2907-2916.	2.2	5

#	Article	IF	CITATIONS
289	Prognostic imaging variables for recurrent laryngeal and hypopharyngeal carcinoma treated with primary chemoradiotherapy: A systematic review and metaâ€analysis. Head and Neck, 2021, 43, 2202-2215.	2.0	5
290	A Randomised Controlled Trial of Consent Procedures for the Use of Residual Tissues for Medical Research: Preferences of and Implications for Patients, Research and Clinical Practice. PLoS ONE, 2016, 11, e0152509.	2.5	5
291	Nutritional interventions in patients with head and neck cancer undergoing chemoradiotherapy: Current practice at the Dutch Head and Neck Oncology centres. European Journal of Cancer Care, 2022, 31, e13518.	1.5	5
292	Skeletal muscle mass at C3 is a strong predictor for skeletal muscle mass at L3 in sarcopenic and non-sarcopenic patients with head and neck cancer. Oral Oncology, 2021, 122, 105558.	1.5	5
293	Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era. Cancers, 2022, 14, 1202.	3.7	5
294	Voice Outcome After Carbon Dioxide Transoral Laser Microsurgery for Glottic Cancer According to the European Laryngological Society Classification of Cordectomy Types – A Systematic Review. Journal of Voice, 2022, , .	1.5	5
295	Detection of residual head and neck squamous cell carcinoma after (chemo)radiotherapy: a pilot study assessing the value of diffusion-weighted magnetic resonance imaging as an adjunct to PET-CT using 18 F-FDG. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, 296-305.e2.	0.4	4
296	Predicting individualized mortality probabilities for patients with squamous cell carcinoma of the maxilla: Novel models with clinical and histopathological predictors. Head and Neck, 2019, 41, 3584-3593.	2.0	4
297	Detecting Bone Invasion of the Maxilla by Oral Squamous Cell Carcinoma: Diagnostic Accuracy of Preoperative Computed Tomography Versus Magnetic Resonance Imaging. Journal of Oral and Maxillofacial Surgery, 2020, 78, 1645-1652.	1.2	4
298	Is There A Role for Limited Parotid Resections for Primary Malignant Parotid Tumors?. Surgeries, 2020, 1, 2-9.	0.6	4
299	Contemporary management of the neck in nasopharyngeal carcinoma. Head and Neck, 2021, 43, 1949-1963.	2.0	4
300	Unilateral versus bilateral nodal irradiation: Current evidence in the treatment of squamous cell carcinoma of the head and neck. Head and Neck, 2021, 43, 2807-2821.	2.0	4
301	Functional imaging to predict treatment response after (chemo) radiotherapy of head and neck squamous cell carcinoma. Quantitative Imaging in Medicine and Surgery, 2013, 3, 231-4.	2.0	4
302	Association of low skeletal muscle mass and systemic inflammation with surgical complications and survival after microvascular flap reconstruction in patients with head and neck cancer. Head and Neck, 2022, 44, 2077-2094.	2.0	4
303	18FDG SUV in the primary tumor and lymph node metastases is not predictive for development of distant metastases in high risk head and neck cancer patients. Oral Oncology, 2015, 51, 536-540.	1.5	3
304	Evaluation of neck node response after radiotherapy: minimizing equivocal results. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 605-608.	6.4	3
305	Differences in cancer gene copy number alterations between Epsteinâ€Barr virusâ€positive and Epsteinâ€Barr virusâ€negative nasopharyngeal carcinoma. Head and Neck, 2018, 40, 1986-1998.	2.0	3
306	New Developments in Sentinel Lymph Node Biopsy Procedure in Localized Oral Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 741.	2.2	3

#	Article	IF	CITATIONS
307	[68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy for sentinel lymph node detection in early-stage oral cavity carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1246-1247.	6.4	3
308	The prognostic impact of micrometastases and isolated tumor cells in early oral squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2021, 278, 5105-5106.	1.6	3
309	Local recurrence and survival after treatment of oral squamous cell carcinoma of the maxilla: A systematic review and meta-analysis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2022, 133, 626-638.	0.4	3
310	Functional decline after surgery in older patients with head and neck cancer. Oral Oncology, 2021, 123, 105584.	1.5	3
311	Arterial calcification on preoperative computed tomography imaging as a risk factor for pharyngocutaneous fistula formation after total laryngectomy. Head and Neck, 2021, , .	2.0	3
312	Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer. Clinical Nutrition, 2022, 41, 177-185.	5.0	3
313	A Comprehensive Grading System for a Magnetic Sentinel Lymph Node Biopsy Procedure in Head and Neck Cancer Patients. Cancers, 2022, 14, 678.	3.7	3
314	Value of cone beam computed tomography for detecting bone invasion in squamous cell carcinoma of the maxilla. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2022, 134, 102-109.	0.4	3
315	Association of preoperative low skeletal muscle mass with postoperative complications after selective neck dissection. International Journal of Oral and Maxillofacial Surgery, 2022, 51, 1389-1393.	1.5	3
316	Correlation and colocalization of HIF-1α and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis. Oral Oncology, 2022, 128, 105862.	1.5	3
317	Is there a place for FDG-PET-CT in early oral cancer patients?. Oral Oncology, 2018, 84, 123-124.	1.5	2
318	Is low or high body mass index in patients operated for oral squamous cell carcinoma associated with the perioperative complication rate?. International Journal of Oral and Maxillofacial Surgery, 2021, 50, 591-597.	1.5	2
319	Standardization for oncologic head and neck surgery. European Archives of Oto-Rhino-Laryngology, 2021, 278, 4663-4669.	1.6	2
320	ECLYPS: Multicenter trial of FDG-PET/CT to detect residual nodal disease in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after chemoradiotherapy (CRT) Journal of Clinical Oncology, 2016, 34, 6021-6021.	1.6	2
321	Esophageal Second Primary Tumors in Patients With Head and Neck Squamous Cell Carcinoma: Incidence, Risk Factors, and Overall Survival. American Journal of Gastroenterology, 2022, 117, 794-797.	0.4	2
322	Cervical Lymph Node Metastases from Central Nervous System Tumors: A Systematic Review. Cancer Management and Research, 2022, Volume 14, 1099-1111.	1.9	2
323	Within-patient comparison between [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [99mTc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2023-2036.	6.4	2
324	Assessing the prognostic value of tumor-infiltrating CD57+ cells in advanced stage head and neck cancer using QuPath digital image analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	2.8	2

#	Article	IF	CITATIONS
325	Letter to the editor. Head and Neck, 2006, 28, 280-282.	2.0	1
326	Time interval between (chemo)radiotherapy and subsequent laryngectomy is not prognostic for post operative complications and survival. European Archives of Oto-Rhino-Laryngology, 2021, 278, 2511-2516.	1.6	1
327	Skeletal muscle mass measurements using head and neck CT imaging in head and neck cancer patients. Radiotherapy and Oncology, 2021, 161, 72-73.	0.6	1
328	Response to: Should ultrasound-guided resection be the new norm for oral tongue resections?. Oral Oncology, 2021, 124, 105473.	1.5	1
329	Detection of sentinel lymph nodes by tilmanocept in oral squamous cell carcinoma. Clinical and Experimental Metastasis, 2022, 39, 417-419.	3.3	1
330	Benign Peripheral Non-cranial Nerve Sheath Tumors of the Neck. Advances in Therapy, 0, , .	2.9	1
331	Reply to Letter to the editor – Is no difference always a good thing? Panayiotis A. Kyzas. Oral Oncology, 2013, 49, e29-e31.	1.5	Ο
332	Head and neck cancer: towards a new paradigm with sentinel node localization. Clinical and Translational Imaging, 2015, 3, 195-202.	2.1	0
333	Radioguided Sentinel Lymph Node Mapping and Biopsy in Oral Cancer. , 2016, , 167-179.		Ο
334	The interobserver agreement in the detection of recurrent HNSCC using MRI including diffusion weighted MRI. European Journal of Radiology, 2018, 105, 134-140.	2.6	0
335	Reply to comment on "Sarcopenia is a prognostic factor for overall survival in elderly patients with head and neck cancer― European Archives of Oto-Rhino-Laryngology, 2019, 276, 2631-2633.	1.6	Ο
336	Comparison of different diagnostic approaches in the management of the clinically negative neck in early oral cancer patients. Cancer, 2021, 127, 1959-1962.	4.1	0
337	Update and external validation of a multivariable prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer Journal of Clinical Oncology, 2021, 39, 6040-6040.	1.6	0
338	Evaluation of a streamlined sentinel lymph-node imaging protocol in early-stage oral cancer. Annals of Nuclear Medicine, 2021, 35, 1353-1360.	2.2	0
339	Osteosarcoma of the head and neck (OHN): A multicenter case series of 79 adult patients in the Netherlands Journal of Clinical Oncology, 2014, 32, 10542-10542.	1.6	0
340	Multidisciplinary Treatment of the Neck. , 2016, , 591-606.		0
341	FGFR1 as a prognostic biomarker and potential therapeutic target in head and neck squamous cell carcinoma Journal of Clinical Oncology, 2016, 34, 6057-6057.	1.6	0
342	Adding shared laughter to optimise shared medicine Journal of Clinical Oncology, 2018, 36, 43-43.	1.6	0

#	Article	IF	CITATIONS
343	Response to "Head and neck cancer diagnoses and faster treatment initiation during COVID-19: Correspondence― Radiotherapy and Oncology, 2022, , .	0.6	0
344	Surgical margins in the resection of oral squamous cell carcinoma under local versus general anesthesia. Oral Oncology, 2022, 125, 105724.	1.5	0
345	Association of histological features with laryngeal squamous cell carcinoma recurrences: a population-based study of 1502 patients in the Netherlands. BMC Cancer, 2022, 22, 444.	2.6	0